Agmatine for Neuropathic pain and Agmatine
Each entry’s own grades, side by side. A grade says how strong the evidence is for one outcome — it does not rank one entry over the other.
Evidence brief
Agmatine for Neuropathic pain
Evidence grade C — One small study
Grade C1 graded outcomerevised Jul 10, 2026
Assembled by the app from other entries in this library. It adds no evidence of its own — follow the links to the entries it draws on.
Compound or practice
Agmatine
An arginine metabolite popular in pre-workouts with almost no human performance evidence.
Grade D2 graded outcomesrevised Jul 10, 2026
A structured monograph in Prometheus's bundled library. Its grades are the monograph's own reading of the evidence, not a peer-reviewed review.
Graded in both
Outcomes are matched by name. Two entries can describe the same outcome in different words, so one listed further down may still be graded in the other.
| Outcome | Agmatine for Neuropathic pain | Agmatine |
|---|---|---|
| Neuropathic pain | Evidence grade CSmall effectlowOne small study | Evidence grade CSmall effectlowOne small study |
Graded only in Agmatine for Neuropathic pain
None — every outcome it grades is graded in both.
Graded only in Agmatine
- Exercise performance Unclear effectEvidence grade D
What each entry says about the other
- Agmatine for Neuropathic pain’s entry · Goes with: Read the full Agmatine monograph
Both columns are read from the entries as they stand in this library. A comparison is not advice to take either one, and it is no substitute for a clinician who knows the person.